Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Classical hematology 1

Conditions

Venous Thromboembolism 11Neoplasms 9Pulmonary Embolism 6Venous Thrombosis 5Thrombosis 3Neoplasm Metastasis 2Myeloproliferative Disorders 2Intracranial Thrombosis 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Mesenteric Ischemia 1Lymphoma 1Hematologic Neoplasms 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × apixaban × Clear all
NCT02958969 2019-12-17

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

Dana-Farber Cancer Institute

Phase 4 Completed
50 enrolled 5 charts
Classical hematologyPlasma cell

Multiple Myeloma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡